Assenagon Asset Management S.A. Raises Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Assenagon Asset Management S.A. lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 48.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 673,289 shares of the company's stock after purchasing an additional 221,196 shares during the quarter. Assenagon Asset Management S.A. owned 1.45% of Pacira BioSciences worth $16,731,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sterling Capital Management LLC boosted its holdings in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares in the last quarter. Ancora Advisors LLC purchased a new stake in Pacira BioSciences during the 4th quarter valued at about $26,000. PNC Financial Services Group Inc. boosted its holdings in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the period. GAMMA Investing LLC boosted its holdings in Pacira BioSciences by 112.8% during the 1st quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock valued at $92,000 after acquiring an additional 1,958 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Pacira BioSciences during the 4th quarter valued at about $103,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Up 0.2%

Shares of NASDAQ:PCRX traded up $0.05 during trading on Tuesday, hitting $24.39. The stock had a trading volume of 351,381 shares, compared to its average volume of 970,754. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $29.61. The company has a market capitalization of $1.13 billion, a PE ratio of -10.70 and a beta of 0.52. The firm's fifty day moving average is $25.50 and its 200 day moving average is $23.73. The company has a quick ratio of 1.99, a current ratio of 2.41 and a debt-to-equity ratio of 0.48.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 5,578 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the transaction, the senior vice president now owns 59,564 shares of the company's stock, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PCRX shares. Wall Street Zen upgraded Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Needham & Company LLC dropped their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, HC Wainwright upped their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.